Incretin-based therapies create unprecedented opportunities to treat obesity and associated cardiometabolic disorders with high efficiency and minimal side effects, motivating new research efforts to increase our understanding of the central mechanisms of action of these drugs and the routes through which they access their functional brain targets to produce sustained weight loss. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.